MARKET

DRRX

DRRX

DURECT
NASDAQ
1.040
+0.110
+11.83%
After Hours: 1.050 +0.01 +0.96% 19:52 05/20 EDT
OPEN
0.9600
PREV CLOSE
0.9300
HIGH
1.040
LOW
0.9300
VOLUME
105.05K
TURNOVER
0
52 WEEK HIGH
7.46
52 WEEK LOW
0.4703
MARKET CAP
32.28M
P/E (TTM)
-1.2019
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at DRRX last week (0513-0517)?
Weekly Report · 19h ago
HC Wainwright & Co. Reiterates Neutral on Durect
Benzinga · 5d ago
Durect Corp: Quarterly Report on Form 10-Q for the Quarter Ended March 31, 2024
Press release · 6d ago
Cutera, Inotiv, Treace Medical Concepts among healthcare movers
Healthcare On the Move: Cutera, Inotiv, Treace Medical Concepts among healthcare movers. S&P 500 Health Care Sector contributes 58% to the index. Harrow and Harrow are among the top gainers in the healthcare sector. Cutera and Inotv are among healthcare companies on the move.
Seeking Alpha · 6d ago
Durect (DRRX) Gets a Buy from Oppenheimer
TipRanks · 6d ago
Durect (DRRX) Receives a Hold from H.C. Wainwright
TipRanks · 6d ago
DRRX Stock Earnings: Durect Misses EPS, Misses Revenue for Q1 2024
Durect just reported results for the first quarter of 2024. The company reported earnings per share of -25 cents. This was below the analyst estimate for -22 cents. Durect also reported revenue of $ million, lower than the estimate for the quarter.
Investorplace · 05/14 00:54
DURECT Corp reports results for the quarter ended in January - Earnings Summary
DURECT Corp reports results for the quarter ended in January. The company reported a quarterly adjusted loss of 25 cents per share. Revenue fell to $ million from a year ago. The average analyst rating on the shares is "buy" for DURECT.
Reuters · 05/13 21:22
More
About DRRX
DURECT Corporation is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol is in clinical development for the potential treatment of alcohol-associated hepatitis, for which United States Food and Drug Administration (FDA) has granted a Fast Track Designation; metabolic dysfunction-associated steatohepatitis is also being explored. Its commercial pharmaceutical products include POSIMIR (bupivacaine solution), PERSERIS (schizophrenia) and Methydur Sustained Release Capsules (ADHD). POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology, is FDA-approved. Its ALZET product line consists of miniature, implantable osmotic pumps and accessories used for research in mice, rats and other laboratory animals.

Webull offers DURECT Corp stock information, including NASDAQ: DRRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DRRX stock methods without spending real money on the virtual paper trading platform.